Project Grant HT9425261E216
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of Colorado-Denver a $907,432 Project Grant effective July 1, 2026 through June 30, 2029 under the Military Medical Research and Development program (CFDA 12.420). The award supports research focused on overcoming resistance to BRAF-directed therapy in advanced thyroid cancer. This research initiative represents a translational oncology effort aligned with the DHA's mission to advance innovative medical solutions...
- Federal Grant Award Summary The University of Colorado-Denver received a $624,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2025, through June 30, 2027. The award supports research focused on targeting androgen receptors as a novel therapeutic strategy for advanced thyroid cancer. This research initiative aligns with the DHA's broader mission to transform healthcare for service members...
- Federal Grant Award Summary The University of Colorado-Denver received a $1.18 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a three-year performance period from June 1, 2026, through May 31, 2029. The award supports research on the use of unconventional immune cells to treat rare melanomas and understand immunotherapy resistance. This research initiative aligns with the DHA's mission to advance biomedical...
- Federal Grant Award Summary The Defense Health Agency awarded the University of Colorado-Denver a $904,982 Project Grant effective June 1, 2026, through May 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). The award supports research to investigate the use of unconventional immune cells in treating rare melanomas and understanding immunotherapy resistance. This research initiative aligns with the Defense Health Agency's mission to advance innovative biomedical...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of Colorado-Denver a $1.4M Project Grant effective July 1, 2026, through June 30, 2029, under the Military Medical Research and Development program (CFDA 12.420). The award supports research focused on enhancing Linker for Activation of T cells (LAT) activity in chimeric antigen receptor (CAR) T cell therapies for Ewing sarcoma treatment. This research initiative represents DHA's commitment to advancing innovative...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $2.87M Project Grant to The Regents of the University of Colorado (doing business as University of Colorado-Denver) on September 1, 2025, under the Military Medical Research and Development program (CFDA 12.420). The four-year award, which extends through August 31, 2029, supports research evaluating the Clinical, Biomarkers, Imaging, and Modifiers (CBI-M) classification system for traumatic brain injury (TBI). This research...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York's Health Sciences Division a $1.645 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research on treating HER2 therapy-resistant brain metastasis using antidepressants, conducted at Columbia's Health Sciences Division facility in New York, NY. This project...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division received a $750,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with a performance period from July 1, 2026 through June 30, 2029. The award funds research to identify novel therapeutic targets that overcome treatment resistance in triple-negative breast cancer (TNBC), a particularly aggressive form of cancer with limited...
- Federal Project Grant Award Summary Colorado State University's Sponsored Programs Division received a $320,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on August 15, 2025, with completion targeted for August 14, 2027. The research project, titled "Overlooked No More: The Impact of the Menstrual Cycle on Neuromuscular Function in Women with Multiple Sclerosis," will be conducted at the...
- Federal Project Grant Award Summary Award Overview The Defense Health Agency (DHA) awarded Dartmouth-Hitchcock Clinic a Project Grant of $5,163,060 under the Military Medical Research and Development program (CFDA 12.420) for research titled "Therapeutic Targeting of the Tumor Microenvironment in Triple-Negative Breast Cancer Patients at High Risk of Relapse and Preclinical Models of Lung Metastases." The award was issued on May 15, 2025, with a performance period extending through May...
The Defense Health Agency (DHA) awarded University of Colorado-Denver $842,067 under the Military Medical Research and Development program (CFDA 12.420) for the project "Overcoming Resistance to BRAF-Directed Therapy in Advanced Thyroid Cancer." The award, initiated July 1, 2026, with completion targeted for June 30, 2029, supports basic and applied biomedical research designed to advance innovative medical solutions for both military service members and the general public. This project delivers hypothesis-driven research and development services focused on understanding and overcoming therapeutic resistance mechanisms in advanced thyroid cancer patients treated with BRAF-directed therapies, contributing to improved cancer treatment outcomes through translational research and biomarker discovery activities. The Military Medical Research and Development program, administered by the DHA, funds research across diverse medical domains including oncology, neurology, immunotherapy, and trauma care through a competitive two-tier peer and programmatic review process. As a comprehensive research university with established federal research infrastructure, University of Colorado-Denver leverages its medical and scientific expertise to conduct the investigational work at its Aurora, Colorado location. This three-year project award aligns with the program's emphasis on precision medicine and cancer research innovations, with anticipated research outputs including mechanisms of therapeutic resistance, potential biomarkers, and evidence supporting enhanced clinical approaches to advanced thyroid cancer management.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $842.1k | 5/15/26 |